written on 04.03.2014

NICE R&D cost request sets orphan drug precedent with Soliris guidance


One way in which it differs, laid out in the HST interim process and methods statement, is that NICE will take into account what could be considered a "reasonable cost" for the medicine. NICE's methods statement specifically says this will be considered…